Carole Huntsman Sells 910 Shares of Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) insider Carole Huntsman sold 910 shares of the company’s stock in a transaction dated Monday, January 26th. The shares were sold at an average price of $493.78, for a total transaction of $449,339.80. Following the sale, the insider owned 9,122 shares in the company, valued at $4,504,261.16. This represents a 9.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Carole Huntsman also recently made the following trade(s):

• On Friday, November 21st, Carole Huntsman sold 1,958 shares of Madrigal Pharmaceuticals stock. The stock was sold at an average price of $553.11, for a total value of $1,082,989.38.

Madrigal Pharmaceuticals Trading Up 0.2%

Shares of MDGL stock opened at $500.39 on Wednesday. The company has a market cap of $11.36 billion, a PE ratio of -38.46, a price-to-earnings-growth ratio of 4.84 and a beta of -1.00. Madrigal Pharmaceuticals, Inc. has a 1 year low of $265.00 and a 1 year high of $615.00. The stock’s 50 day simple moving average is $556.89 and its two-hundred day simple moving average is $462.94. The company has a debt-to-equity ratio of 0.54, a current ratio of 3.44 and a quick ratio of 3.26.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last released its earnings results on Tuesday, November 4th. The biopharmaceutical company reported ($5.08) earnings per share for the quarter, missing the consensus estimate of ($2.01) by ($3.07). Madrigal Pharmaceuticals had a negative net margin of 39.04% and a negative return on equity of 41.50%. Research analysts predict that Madrigal Pharmaceuticals, Inc. will post -23.47 earnings per share for the current year.

Wall Street Analysts Forecast Growth

MDGL has been the subject of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Madrigal Pharmaceuticals in a research note on Thursday, January 22nd. JMP Securities set a $527.00 target price on Madrigal Pharmaceuticals in a research report on Wednesday, November 5th. Wolfe Research set a $579.00 price target on Madrigal Pharmaceuticals in a report on Tuesday, January 6th. Canaccord Genuity Group raised their price target on Madrigal Pharmaceuticals from $526.00 to $587.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Finally, UBS Group set a $900.00 price objective on Madrigal Pharmaceuticals in a report on Friday, December 19th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Madrigal Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $654.73.

Hedge Funds Weigh In On Madrigal Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Madrigal Pharmaceuticals by 40.3% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,978 shares of the biopharmaceutical company’s stock valued at $1,734,000 after acquiring an additional 855 shares in the last quarter. Farther Finance Advisors LLC boosted its position in shares of Madrigal Pharmaceuticals by 34.6% in the 4th quarter. Farther Finance Advisors LLC now owns 140 shares of the biopharmaceutical company’s stock worth $82,000 after purchasing an additional 36 shares in the last quarter. Valley National Advisers Inc. grew its stake in Madrigal Pharmaceuticals by 312.8% during the 4th quarter. Valley National Advisers Inc. now owns 161 shares of the biopharmaceutical company’s stock worth $93,000 after buying an additional 122 shares during the last quarter. James J. Burns & Company LLC acquired a new position in Madrigal Pharmaceuticals during the 4th quarter valued at about $310,000. Finally, Choreo LLC purchased a new stake in Madrigal Pharmaceuticals in the fourth quarter valued at about $222,000. 98.50% of the stock is currently owned by institutional investors.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH.